IOV-3001 not checked

Iovance Biotherapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.”In the company’s words, NCT06940739 on ClinicalTrials.gov
Tested for
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Main trialPhase 1/2
“A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.”In the company’s words, NCT06940739 on ClinicalTrials.gov

Other drugs for Unresectable Melanoma

All 195 drugs for Unresectable Melanoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jun 2032 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IOV-3001

Following is part of Solo: you see every change to IOV-3001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in